Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 16
2021 65
2022 90
2023 66
2024 31

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Results by year

Filters applied: . Clear all
Page 1
Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
Mora E, Montoro J, Balaguer A, Rovira M, Cabrero M, Heras I, Ribera JM, Antelo G, Martin AA, Lopez Godino O, Torrent A, Villalba M, Chorao P, Sanz MA, Sanz J; Grupo Español de Trasplante Hematopoyético (GETH). Mora E, et al. Bone Marrow Transplant. 2024 May 16. doi: 10.1038/s41409-024-02298-z. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38755458
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison.
Beelen DW, Iacobelli S, Koster L, Eikema DJ, van Biezen A, Stölzel F, Ciceri F, Bethge W, Dreger P, Wagner-Drouet EM, Reményi P, Stelljes M, Markiewicz M, McLornan DP, Yakoub-Agha I, Mohty M. Beelen DW, et al. Bone Marrow Transplant. 2024 May;59(5):670-679. doi: 10.1038/s41409-024-02241-2. Epub 2024 Feb 21. Bone Marrow Transplant. 2024. PMID: 38383713 Free PMC article. Clinical Trial.
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji RM, Griskevicius L, Salmenniemi U, Rambaldi A, Mielke S, Kulagin A, Passweg J, Luft T, Gedde-Dahl T, Forcade E, Helbig G, Stelljes M, Castilla-Llorente C, Spyridonidis A, Brissot E, Ciceri F, Mohty M. Nagler A, et al. Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02284-5. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38615143
Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.
Donadel CD, De Santis GC, Gonçalves TE, Pires BG, Palma LC, Gava F, Guerino-Cunha RL, Faria JTB, Silva GVA, Darrigo-Junior LG, Fatobene G, Rocha V, Covas DT, Calado RT, Clé DV. Donadel CD, et al. Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02283-6. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38615142 No abstract available.
Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study.
Shen Y, Liu M, Shen D, Chu M, Li X, Zhang X, Fan Y, Chen J, Wu D, Hu S, Xu Y. Shen Y, et al. Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02280-9. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38615141 No abstract available.
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Maffini E, Labopin M, Kröger N, Finke J, Stelljes M, Schroeder T, Einsele H, Tischer J, Bornhäuser M, Bethge W, Brecht A, Rösler W, Dreger P, Schäfer-Eckart K, Passweg J, Blau IW, Nagler A, Ciceri F, Mohty M. Maffini E, et al. Bone Marrow Transplant. 2024 Mar 30. doi: 10.1038/s41409-024-02275-6. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38555412
Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.
Park S, Bang SY, Kwag D, Lee JH, Kim TY, Lee J, Min GJ, Park SS, Yahng SA, Jeon YW, Shin SH, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Lee JW, Kim HJ. Park S, et al. Bone Marrow Transplant. 2024 Jun;59(6):813-823. doi: 10.1038/s41409-024-02255-w. Epub 2024 Mar 4. Bone Marrow Transplant. 2024. PMID: 38438648
A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma.
Hirose A, Koh H, Nakamae M, Nakashima Y, Nishimoto M, Okamura H, Makuuchi Y, Kuno M, Takakuwa T, Ido K, Sakatoku K, Hino M, Nakamae H. Hirose A, et al. Bone Marrow Transplant. 2024 May;59(5):695-698. doi: 10.1038/s41409-024-02231-4. Epub 2024 Feb 14. Bone Marrow Transplant. 2024. PMID: 38355910 No abstract available.
221 results